CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 107 enrolled
Drug / intervention
nab-Paclitaxel +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02301143
NCT02301143Phase 2Completed
CompareCT.gov

Nab-paclitaxel (Abraxane) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC): An International, Open-label, Multi-center, Phase 2 Study (LAPACT).

Celgene·interventional·Posted Nov 25, 2014·Updated Mar 20, 2019

In Brief

A Phase 2 clinical trial evaluating nab-Paclitaxel, Gemcitabine, and 3 other interventions for Pancreatic Neoplasms. Completed, enrolled 107 participants across 42 sites in 5 countries.

Detailed Summary

This clinical study is in subjects who are 18 years old or older with locally advanced pancreatic cancer who have not received prior treatment for their pancreatic cancer. The study treats all subjects with nab-Paclitaxel plus gemcitabine for approximately 6 months of treatment. Subjects who complete the treatment will choose, with their treating physicians, what additional treatment should be given: more nab-Paclitaxel plus gemcitabine, Chemoradiation therapy, or surgery to treat the locally advanced pancreatic cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Neoplasms
CountriesCanada, France, Italy, Spain, United States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 25, 2014
Enrollment StartApr 21, 2015
Primary CompletionNov 21, 2017
Study CompletionApr 26, 2018
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 11.6 years ago

Interventions

nab-Paclitaxeldrug

Gemcitabinedrug

Chemoradiationdrug

Capecitabinedrug

Surgeryprocedure

Surgical intervention